ホーム>>Infectious Disease>> Fungal Diseases>> Candidiasis>>Milbemycin A4 oxime

Milbemycin A4 oxime (Synonyms: 5-Ketomilbemycin A4 oxime, 5-Oxomilbemycin A4 5-oxime)

カタログ番号GC44195

ミルベマイシンA4オキシムは、昆虫殺虫および線虫殺虫活性を持つ化合物であるミルベマイシンオキシムの成分であり、ミルベマイシンA4の誘導体です。

Products are for research use only. Not for human use. We do not sell to patients.

Milbemycin A4 oxime 化学構造

Cas No.: 93074-04-5

サイズ 価格 在庫数 個数
1mg
$370.00
在庫あり
5mg
$1,482.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Milbemycin A4 oxime is a derivative of milbemycin A4 and a component of milbemycin oxime , compounds that both have insecticidal and nematocidal activity. Milbemycin A4 oxime (0.05 mg/kg) reduces the number of microfilariae of the heartworm D. immitis in naturally infested dogs. It inhibits the growth of clinical isolates of C. glabrata with MIC80 values ranging from 16 to greater than 32 μg/ml. Milbemycin A4 oxime (2.5 μg/ml) blocks efflux of fluconazole from a clinical isolate of C. glabrata, but not from a strain lacking the efflux pumps CgCDR1 and PDH1, and reduces the MICs of fluconazole and 4-nitroquinoline 1-oxide in wild-type C. glabrata. It enhances adriamycin-induced inhibition of cell growth, as well as increases the intracellular accumulation of adriamycin and the P-glycoprotein substrate rhodamine 123 , in adriamycin-resistant, but not -sensitive, MCF-7 breast cancer cells in a concentration-dependent manner.

レビュー

Review for Milbemycin A4 oxime

Average Rating: 5 ★★★★★ (Based on Reviews and 28 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Milbemycin A4 oxime

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.